Navigation Links
Some skin cancer may be mediated by primary cilia activity
Date:8/23/2009

Tiny, solitary spikes that stick out of nearly every cell in the body play a central role in a type of skin cancer, new research has found. The discovery in mice shows that the microscopic structures known as primary cilia can either suppress or promote this skin cancer, depending on the mutation triggering the disease.

The finding suggests that drugs that boost or block primary cilia activity could offer a new strategy against cancer.

Unlike the more familiar motile cilia, primary cilia do not move, and only one pokes out of each cell. They have recently been discovered to play an essential role in assuring normal embryological development.

The new study focused on basal cell carcinoma, the most common cancer in the United States. It is published in the August 23, 2009 advanced online issue of "Nature Medicine." A companion article in the same issue reports a similar discovery regarding a type of brain tumor in children known as medulloblastoma. (See related UCSF news release on this finding.)

The two studies were led by scientists at the University of California, San Francisco, and they are the first demonstrations that primary cilia are required for some kinds of cancer. They are also the first reports that these cilia can protrude from cancer cells, as they do from most normal cells.

If the basal cell carcinoma finding is confirmed in people, the discovery raises the possibility of new cancer treatment strategies, said Jeremy Reiter, MD, PhD, senior author of that paper. Reiter is assistant professor of biochemistry and biophysics, an investigator at the Cardiovascular Research Institute, the Diabetes Center and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF. In July, President Obama named him as a recipient of the Presidential Early Career Award for Scientists and Engineers for his research on the links between cilia and cancer.

Although they are relegated to the outsk
'/>"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Current research suggests that a common oral bact...ted report by Nichols et al, "Unique Lipids from a...LR2 Ligands Capable of Enhancing Autoimmunity," ap...Journal of Pathology . , Multiple sclerosis (MS)...ain and spinal cord, affects nearly 1 in 700 peopl...
(Date:11/23/2009)...The only swine vaccine available for the H1N1 viru... with the virus. The vaccination marks the first t...d with the pandemic flu., Iowa State University,...ped the vaccine this summer and has been shipping ...s and Illinois for several weeks., The latest va...
(Date:11/23/2009)...vember 16, 2009 -- A USDOE and USDA study conclude...pland, and cropland pasture could be converted fro...ses, such as switchgrass, from which biomass could...omically viable production of a perennial grass mo...mass are removed annually is expected to require n...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 1Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 2
...h, and still the University of Wisconsin-Madison S...requests. Since 1998, the school,s oncology depar...r dogs diagnosed with melanoma. Though it is sti...over the nation have wanted to participate in the ...heir pet. , After promising results from work done...
...we carry this activity out through the placenta an...velopment, the lungs of the foetus are filled with... activates this respiration surface. But the main ...ungs are not well formed. Moreover, they often lac...pids that avoids the lungs folding in on themselve...
...billion-base human genome play a vital role in a b...chers from the Wellcome Trust Sanger Institute and...r Medical Research, together with international co...ps of differences implicated in disease as well as... , The Major Histocompatibility Complex (MHC) con...
Other Biology News:Canine cancer vaccine program shows early promise 2Liquid ventilation 2Researchers map of genetic variations implicated in disease 2Researchers map of genetic variations implicated in disease 3
(Date:11/19/2009)...SEATTLE, Nov. 19 Omeros ...ited financial results for the third quarter ended...ptember 30, 2009, Omeros reported a net loss of $3...et loss of $7.4 million, or $2.54 per share, for t...September 30, 2009, the Company reported a net los...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire/ ...filed on November 16th, 2009 Flibanserin in the,in...nesia in Parkinson,s,disease for orphan drug statu...EMEA). Levodopa-induced dyskinesia is a complicati...,s and a serious burden to some of those,affected,...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... Time -, SAN FRANCISCO, Nov. 10 Medivation, Inc....progress and financial,results for the quarter end...ented another quarter of significant,achievement a... partnering,agreement with Pfizer for Dimebon. Thi...d-class partner capable of maximizing global,comme...
... Discuss the Data and Ongoing ...Nov. 10 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...1 clinical trial, one of Sangamo,s three Phase 2 c...am to develop SB-509 for diabetic,neuropathy (DN)....f the,drug is well tolerated in subjects with mild...
...es of Non-Core Product Lines -, HOPKINTON, Mass.,...LP ) today reported third quarter financial,result...divestitures: the,sale of its AutoTrace(R) product...he sale of its Pharmaceutical Development and Qual...on for $15.8 million. Revenues for the,quarter wer...
Other Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
...ein Phosphatase-2A (PPase-2A) is a serine/threonin... It is isolated as the heterodimer of 60kDa (A) an...phorylate the a-subunit of phosphorylase kinase. W...oad substrate specificity and may play a regulator...
...oskan is a high performance spectral scanning mult.... With the advanced SkanIt Software it offers supe...y assay development. Varioskan provides unlimited ...ime-resolved fluorescence and photometric assays a...
...ctively condenses and traps a wide variety of solv... pump oil. Easy-to-use glass condensation flask (G...self contained jar for easy draining. Rapid coolin...4 o C temperature traps high volatile solvents ...
Immulon 2HB from Thermo Scientific
Biology Products: